Scaphoid fracture is most common in young individuals of working age. Without adequate diagnosis and treatment, long-term results are poor. Operative treatment is being recommended increasingly often instead of a long time in cast, although there is no evidence-based support for its superiority. The present thesis focuses on diagnostic problems and therapeutic consequences of acute scaphoid fractures and of scaphoid reconstruction when other treatments have failed. Simultaneous plain radiographs and computed tomography were done in 97 injured wrists. Structural assessments of plain radiography images were highly predictive with respect to the risk of having a displaced or comminute fracture as diagnosed on computed tomography. Any finding of a gap or step-off > 0.5 mm, the presence of an intermediate fragment or a dorsal lunate tilt of ≥ 15° identified 81 % of fractures that were displaced or comminuted when investigated with computed tomography. Eighty-three patients were randomly allocated to and received either nonoperative treatment in cast or operative treatment with the aim of assessing long-term outcome of the two treatment options. Fifty-two of the patients were occupationally active. From an occupational perspective with an early return to work, surgical treatment was superior in individuals with manual employment, and from a health economic perspective conservative treatment was superior in non-manual workers. Patients treated for scaphoid fractures generally do well up to 13 years after the injury based on limb-specific outcome scores. No benefits were identified with operative treatment compared to non-operative treatment in cast. On the contrary, there was an increased risk for osteoarthritis in the scaphotrapezial joint in those who were operated. The patient-rated long-term results of silicone implant arthroplasty were good, with pain relief and reasonable hand function in many patients up to 20 years after surgery.

Τα ΑΕΕ είναι η πρώτη αιτία αναπηρίας και η τρίτη αιτία θανάτου παγκοσμίως. Επίσης οι ασθενείς με ΑΕΕ είναι οι συχνότεροι χρήστες των υπηρεσιών υγείας. Παράλληλα, στη χώρα μας δαπανάται ετησίως το 10% του Ακαθάριστου Εγχώριου Προϊόντος (ΑΕΠ) για την υγεία σε σχέση με το μέσο όρο του 8,9% των χωρών του Οργανισμού Οικονομικής Συνεργασίας και Ανάπτυξης (ΟΟΣΑ). Στόχος της μελέτης είναι η οικονομική αξιολόγηση του ενδο-νοσοκομειακού κόστους ασθενών με οξύ ΑΕΕ στην Ελλάδα καθώς επίσης και ο προσδιορισμός ανεξάρτητων παραγόντων που επηρεάζουν το κόστος νοσηλείας. Καταγράφηκαν δημογραφικά και κλινικά χαρακτηριστικά σε 429 συνεχόμενους ασθενείς με οξύ ΑΕΕ (ισχαιμικό ή αιμορραγικό) που εισήχθησαν σε όλες τις κλινικές του Πανεπιστημιακού Γενικού Νοσοκομείου Πατρών για διάστημα 18 μηνών. Υπολογίσαμε το κόστος, για κάθε ασθενή ατομικά, από την ώρα της εισβολής του ΑΕΕ έως την έξοδό του από το νοσοκομείο. Το κόστος μετρήθηκε σε ευρώ (€) και σύμφωνα με τις πραγματικές δαπάνες του νοσοκομείου. Η μέση ηλικία των ασθενών ήταν 68.9 (±12.7) έτη και η διάρκεια νοσηλείας ήταν 10.9 (±7.9) ημέρες. Οι 345 ασθενείς (80%) είχαν ισχαιμικό ΑΕΕ και 84 (20%) είχαν πρωτοπαθή ενδοεγκεφαλική αιμορραγία. Το άμεσο ενδο-νοσοκομειακό κόστος νοσηλείας όλων των ασθενών με οξύ ΑΕΕ ανήλθε στα 1.551.445,00 € για μια συνολική διάρκεια νοσηλείας 4.674 ημερών (331,9 € ανά ημέρα νοσηλείας). Το μέσο ενδονοσοκομειακό κόστος ανά ασθενή με ΑΕΕ ήταν 3.624,9(±2695.4) €. Το 59% του συνολικού κόστους αποδόθηκε στο κόστος "κλίνης και προσωπικού", (6%) "προ εισαγωγής", (13%) "εργαστηριακό έλεγχο", (6%) "απεικονιστικό έλεγχο", (8%) "αποκλειστική νοσηλευτική φροντίδα", (7%) "φαρμακευτική αγωγή", (0.6%) "θεραπεία αποκατάστασης" και (0.7%) "διάφορα έξοδα". Τα αιμορραγικά ΑΕΕ είχαν σημαντικά μεγαλύτερο κόστος από τα ισχαιμικά ΑΕΕ (μέσο 5305.4 και 3.214,5 €, αντίστοιχα). Μεταξύ των υπότυπων των ισχαιμικών ΑΕΕ το συνολικό μέσο κόστος ήταν σημαντικά χαμηλότερο για τα "κενοτοπιώδη" έμφρακτα (2328.7±1100.2 €). Η διάρκεια νοσηλείας είχε υψηλή συσχέτιση με το συνολικό ενδο-νοσοκομειακό κόστος. Η πολυπαραγοντική γραμμική ανάλυση παλινδρόμησης έδειξε ότι το τμήμα εισαγωγής, η βαρύτητα του ΑΕΕ στην εισαγωγή, ο τύπος του ΑΕΕ και η κατάσταση εξόδου ήταν ανεξάρτητοι παράγοντες του κόστους. Αν επιθυμούμε τη συγκράτηση του νοσοκομειακού κόστους, θα πρέπει να ληφθούν υπόψη πολιτικές διοίκησης που στοχεύουν στη μείωση της διάρκειας νοσηλείας. / Stroke is the first cause of disability and the third cause of death worldwide. Moreover, in the western countries, the stroke patients are the most frequent users of all the health services and the hospital budgets. At the same time, 10% of the Gross Domestic Product (GDP) is annually spent on health in relation with the average 8.9% of the Organisation for Economic Co-operation and Development (OECD) countries. Aim of this study is the economic evaluation on the in-hospital cost of patients with an acute stroke in Greece and the identification of potential independent factors influencing this cost. Demographic and clinical data were recorded on 429 consecutive patients with an acute stroke (ischemic and hemorrhagic), admitted to the University General Hospital of Patras during a period of 18 months. We calculated the cost, individually for each patient, from the stroke onset until the discharge from the hospital. The cost was measured in euro (€), according to the real expenditure of hospital. Mean age was 68.9 (±12.7) years and length of stay (LOS) was 10.9 (±7.9) days. In all, 345 patients (80%) had an ischemic stroke and 84 (20%) had a primary intracerebral hemorrhage. The direct in-hospital cost of all stroke patients, 1.551.445,00 €, accounted for a total hospitalisation of 4.674 days (331.9 € per day in hospital). The mean in-hospital cost per patient was 3.624,9 (±2695.4) €. The 59% of the total cost concerns the cost of "bed and staff", (6%) "pre-hospital cost", (13%) "laboratory investigations", (6%) "imaging investigations", (8%) "supportive nursing", (7%) "medication", (0.6%) "rehabilitation therapy" and (0.7%) "other expenses". Hemorrhagic strokes were significantly more expensive than the ischemic strokes (mean 5305.4 (± 4204.8) € and 3214,5 (±1976.2) € respectively). Amongst ischemic stroke subtypes the mean total cost was significantly lower for lacunar strokes (2328.7 ± 1100.2 €). The length of stay was highly correlated with in-hospital total cost. Multivariate linear regression model showed that the admission ward, stroke severity on admission, stroke type and status discharge were independent predictors of cost. In order to withhold the hospital cost, policies of administration that aiming to the reduction of length of stay should be taken into consideration.

Thesis (Ph.D.)--University of Tennessee Health Science Center, 2006. / Title from title page screen (viewed on October 26, 2007 ). Research advisor: Mona Newsome Wicks, Ph.D., RN. Document formatted into pages (xii, 174 p. : ill.) Vita. Abstract. Includes bibliographical references (p. 115-132).

Lic.-avh. (sammanfattning) Stockholm : Karolinska institutet, 2007. / Härtill 2 uppsatser.

Diss. (sammanfattning) Stockholm : Karol inst., 2003. / Härtill 6 uppsatser. ISBN tilldelat efter tryckningen.

Diss. (sammanfattning) Stockholm : Karol. inst., 2002. / Härtill 5 uppsatser.

Submitted by Marlene Santos (marlene.bc.ufg@gmail.com) on 2017-09-05T16:25:22Z No. of bitstreams: 2 Tese - Ana Laura de Sene Amâncio Zara - 2017.pdf: 3959463 bytes, checksum: 51394e12c85247544283c6fdfd6f2bf6 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Approved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2017-09-15T15:06:02Z (GMT) No. of bitstreams: 2 Tese - Ana Laura de Sene Amâncio Zara - 2017.pdf: 3959463 bytes, checksum: 51394e12c85247544283c6fdfd6f2bf6 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Made available in DSpace on 2017-09-15T15:06:03Z (GMT). No. of bitstreams: 2 Tese - Ana Laura de Sene Amâncio Zara - 2017.pdf: 3959463 bytes, checksum: 51394e12c85247544283c6fdfd6f2bf6 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2016-08-02 / Conselho Nacional de Pesquisa e Desenvolvimento Científico e Tecnológico - CNPq / Outro / Introduction: dengue cost estimates are important to support complete and useful economic evaluations for decision making regarding the incorporation of new technologies, such as vaccines and alternative strategies to control Aedes. Objectives: to estimate the health services utilization (HSU) for outpatients and hospitalized in the public and private sectors, and severity of the disease, in 2012-2013; identify possible sources of data and methodologies for dengue cost estimates in Brazil, considering primary and secondary sources of data; and estimate the total costs of dengue in Brazil, in 2013-2014, considering costs of the disease and control program costs. Methods: for HSU was conducted a multicenter study in six Brazilian capitals, from questionnaires and medical records. For the cost of illness (COI) and the cost of control program were used various sources of information, from microcusteio and macrocusteio methods as data availability. Results: for the HSU study attended 2,035 patients, of whom 1,167 (57.3%) were women, 1,657 (81.4%) were outpatients, 378 (18.6%) were hospitalized, 1,361 (66 9%) patients were in the public sector, and 398 (19.6%) were children (≤ 14 years). In the public sector, patients underwent an average of 1.9 visit, and hospital patients were on average 4.5 medical visits. In the private sector, the patients were, on average, 2.2 visits, and hospital patients were on average 5.1 medical visits. The vast majority of hospitalized patients had complete blood count, platelet count and hematocrit performed, received antipyretic/analgesic, in both public and private sectors. In 2013-2014, the cost of the dengue control program was US$1.2 billion, with 23% corresponding to federal costs and 77% to municipal costs. The costs of the disease varied according to the sources of information. If primary sources were used, direct medical costs amounted to US$1.2 billion, and from secondary sources (HSU), the costs were US$330.2 million. Indirect costs amounted to US$5.2 million, considering the primary sources. Conclusion: HSU patterns varied significantly according to the health sector and the severity of the disease. In general, the pattern of HUS complies with the guidelines of the MS. In 2013-2014, the total cost of dengue ranged from US$1.53 billion to US$1.69 billion. If the number of underreporting cases was adjusted, costs ranged from US$6.86 billion to US$7.78 billion. Dengue imposes substantial costs to the health and economy in Brazil. It is expected that these results can contribute to the economic and welfare planning essential for the sustainability of the dengue control program in Brazil, which generally has its costs underestimated. / Introdução: estimativas de custos da dengue são importantes para subsidiar avaliações econômicas completas e úteis para tomada de decisões quanto à incorporação de novas tecnologias, como vacinas e estratégias alternativas de controle do Aedes. Objetivos: estimar a utilização de serviços de saúde (USS) pelos pacientes ambulatoriais e hospitalizados, nos setores público e privado, e por gravidade da doença, em 2012-2013; identificar possíveis fontes de dados e metodologias para estimativas de custos da dengue no Brasil, considerando fontes primárias e secundárias de dados; e estimar os custos totais da dengue no Brasil, em 2013-2014, considerando custos da doença e custos do programa de controle. Métodos: para USS foi realizado um estudo multicêntrico em seis capitais brasileiras, a partir de questionários e prontuários médicos. Para o custeio da doença e do programa de controle foram utilizadas variadas fontes de informação, a partir de métodos de microcusteio e macrocusteio conforme disponibilidade dos dados. Resultados: para o estudo de USS participaram 2.035 pacientes, dos quais, 1.167 (57,3%) eram do sexo feminino, 1.657 (81,4%) eram pacientes ambulatoriais, 378 (18,6%) foram hospitalizados, 1.361 (66,9%) pacientes eram do setor público, e 398 (19,6%) eram crianças (≤ 14 anos). No setor público, os pacientes realizaram, em média, 1,9 consulta, e os pacientes hospitalizados receberam, em média 4,5 visitas médicas. No setor privado, os pacientes realizaram, em média, 2,2 consultas, e os pacientes hospitalizados receberam, em média 5,1 visitas médicas. A grande maioria dos pacientes hospitalizados teve hemograma completo, contagem de plaquetas e hematócrito realizados e recebeu antipirético/analgésico, em ambos os setores público e privado. Em 2013-2014, o custo do programa de controle da dengue foi de US$1,2 bilhão, sendo 23% correspondente aos custos federais e 77% aos custos municipais. Os custos da doença variaram de acordo com as fontes de informação. Se utilizadas as fontes primárias, os custos diretos médicos chegaram a US$1,2 bilhão, e por fontes secundárias (USS), os custos foram de US$330,2 milhões. Os custos indiretos chegaram a US$5,2 milhões considerando as fontes primárias. Conclusão: os padrões de USS variaram significativamente de acordo com o setor de saúde e com a gravidade da doença. Em geral, o padrão de USS está em conformidade com as orientações do MS. Em 2013-2014, o custo total da dengue variou entre US$ 1,53 bilhão e US$ 1,69 bilhão. Se ajustado o número de casos subnotificados, os custos variam de US$6,86 bilhões a US$7,78 bilhões. A dengue impõe custos substanciais para a saúde e a economia no Brasil. Espera-se que esses resultados possam contribuir para o planejamento econômico e assistencial imprescindíveis para a sustentabilidade do programa de controle da dengue no Brasil, que, em geral, tem seus custos subestimados.

Submitted by Cássia Santos (cassia.bcufg@gmail.com) on 2017-06-21T13:42:52Z No. of bitstreams: 2 Tese - Sheila Elke Araújo Nunes - 2014.pdf: 4139252 bytes, checksum: 113368e043fc53148e1cd7b8b50b2632 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Approved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2017-07-10T13:36:29Z (GMT) No. of bitstreams: 2 Tese - Sheila Elke Araújo Nunes - 2014.pdf: 4139252 bytes, checksum: 113368e043fc53148e1cd7b8b50b2632 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Made available in DSpace on 2017-07-10T13:36:29Z (GMT). No. of bitstreams: 2 Tese - Sheila Elke Araújo Nunes - 2014.pdf: 4139252 bytes, checksum: 113368e043fc53148e1cd7b8b50b2632 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2014-12-18 / Introduction: Estimate the costs of treatment of pneumococcal diseases can aid the understanding of reduced economic burden of these after introduction of the pneumococcal conjugate vaccine (PCV), as run in Brazil, in March 2010, which introduced the PCV10 valiant in the National Program Immunization (NPI) for children between 2 and 23 months of age. Cost-effectiveness analysis (CEA) before the introduction indicated that the vaccine was cost-effective (R $ 24.930 / Daly avoided - Disability Adjusted Life Years), in the SUS perspective. Disease burden and the cost of the vaccine were identified as the main drivers of the results for sensitivity analysis. Objectives: Estimate the costs of pneumococcal disease and to evaluate the ratio of incremental cost-effectiveness (ICER) of implementing the PCV-10 brave after introduction into INP Brazil. Methods: Three steps have been performed in the SUS perspective: 1) cost of illness study: medical charts of children 28 days to 35 months of age hospitalized with clinical suspicion of bacterial pneumonia were reviewed to estimate the costs of pneumonia and to other syndromes costs were estimated by therapeutic guidelines; 2) comparison between the three methods of funding: (i) bottom-up / micro-costing by chart review; (ii) top-down / micro-costing through therapeutic guidelines; and (iii) top-down / gross-costing, through reimbursement paid by the SUS. 3) CEA: the strategy to vaccinate with PCV-10 was compared to the non-vaccination. The model used was the PneuModel. In acute otitis media from all causes, pneumococcal meningitis, pneumococcal sepsis and pneumococcal pneumonia were considered. Costs were obtained by microcusteio, epidemiological data from primary studies of population-based, dose costs and vaccination coverage in INP. The discount rate was 5%. Sensitivity analysis was conducted to test the robustness and variability of the model parameters. Results: The cost of study of hospitalized pneumonia records of 52 cases of severe pneumonia and 7 of very serious pneumonia were reviewed. Statistical analyzes of severe pneumonia data revealed that there is difference between the costing methodologies (p=0,015) and to compare the estimated costs by these methods there was no difference between the cost of compensation and the cost for therapeutic guideline (p=0,241). At ACE, annually, vaccination with PCV-10 would prevent 3,942 cases of the disease and 16,514 years of life lost in a cohort of children <1 year. The ICER was R $ 14,230 per DALY averted. In sensitivity analysis, the model was sensitive to variations in incidence and mortality of pneumonia and pneumococcal meningitis. Conclusions: The cost for therapy guideline, uncommonly used in disease cost estimates, was an alternative to funding for compensation, heavily used technique and lower accuracy. After introduction of ICER, using primary data revealed that PCV-10 is a low-cost intervention, as suggested by WHO (<1GDP / per capita - in Brazil, in 2010, US $ 10.933) and, ICER less than previous ACE. Despite uncertainties in critical parameters of the model, using secondary data, ACE can provide evidence to support decision making. After the implementation analysis can result in more accurate estimates and provide evidence to continue vaccination. / Introdução: Estimar os custos do tratamento das doenças pneumocócicas podem auxiliar no conhecimento da redução da carga econômica destas após introdução da vacina anti-pneumocócica conjugada (VPC), como corrido no Brasil, em março de 2010, que introduziu a VPC-10 valente no Programa Nacional de Imunização (PNI), para crianças entre 2 e 23 meses de idade. Análise de custo-efetividade (ACE) antes da introdução indicou que a vacina era custo-efetiva (R$ 24,930/Daly evitado – do inglês, Disability Adjusted Life Years), na perspectiva do SUS. Carga da doença e os custos da vacina foram identificados como os principais direcionadores do resultado para análise de sensibilidade. Objetivos: Estimar os custos da doença pneumocócica e avaliar a razão de custo-efetividade incremental (RCEI) da implementação da VPC-10 valente após introdução no PNI do Brasil. Métodos: Três etapas foram executadas, aplicadas a perspectiva do SUS: 1º) estudo de custo de doenças: prontuários de crianças com 28 dias a 35 meses de idade internadas por suspeita clínica de pneumonia bacteriana foram revisados para estimar os custos da pneumonia e para demais síndromes os custos foram estimados por diretrizes terapêuticas; 2º) comparação entre as três metodologias de custeio: (i) bottom-up/micro-costing através da revisão de prontuários; (ii) top-down/micro-costing através de diretriz terapêutica; e (iii) top-down/gross-costing através de ressarcimento pago pelo SUS. 3º) ACE: a estratégia de vacinar com a VPC-10 foi comparada com a não vacinação. O modelo empregado foi o PneuModel. Neste, otite média aguda por todas as causas, meningite pneumocócica, sepse pneumocócica e pneumonia pneumocócica foram consideradas. Os custos foram obtidos por microcusteio, dados epidemiológicos a partir de estudos primários de base populacional, custos da dose e de cobertura vacinal no PNI. A taxa de desconto aplicada foi de 5%. Análise de sensibilidade foi conduzida para testar a robustez e variabilidade de parâmetros do modelo. Resultados: No estudo de custo da pneumonia hospitalizada prontuários de 52 casos de pneumonias graves e 7 de pneumonias muito graves foram revisados. Análises estatísticas dos dados de pneumonias graves revelaram que há diferença entre as metodologias de custeio (p=0,015) e ao comparar os custos estimados por estas metodologias não houve diferença entre o custeio por ressarcimento e o custeio por diretriz terapêutica (p=0,241). Na ACE, anualmente, a vacinação com VPC-10 evitaria 3.942 casos da doença e 16.514 anos de vida perdidos em uma coorte de crianças <1 ano. A RCEI foi de R$ 14.230 por DALY evitado. Na análise de sensibilidade, o modelo foi sensível às variações de incidência e letalidade de pneumonia e meningite pneumocócica. Conclusões: O custeio por diretriz terapêutica, pouco empregado nas estimativas de custo de doença, se mostrou uma alternativa ao custeio por ressarcimento, técnica muito utilizada e de menor acurácia. A RCEI pós introdução, com dados primários, revelou que a VPC-10 é uma intervenção de baixo custo, como sugerido pela OMS (<1PIB/per capita – no Brasil, em 2010, R$ 10,933) e, com menor RCEI que ACE anterior. Mesmo com incertezas em parâmetros críticos do modelo, usando dados secundários, ACE podem fornecer evidências para apoiar tomadas de decisões. Analise pós-introdução pode resultar em estimativas mais precisas e fornecer evidências para continuar a vacinação.

Introdução: As avaliações econômicas em saúde (AES) têm participado como ferramenta de apoio ao processo de decisão no setor de Saúde. No Brasil, seu uso passou a ser amplamente difundido na última década, já sendo obrigatória sua apresentação em processos de incorporações de novas tecnologias no sistema único de saúde. Embora muitas avaliações econômicas de saúde tenham sido conduzidas, nenhum estudo revisou sistematicamente a produção e qualidade das avaliações brasileiras. Objetivo: Revisar sistematicamente e avaliar a qualidade do relato dos estudos publicados de avaliação econômica de tecnologias em saúde desenvolvidos no Brasil. Métodos: Foi conduzida uma revisão sistemática incluindo AES completas e parciais desenvolvidas no Brasil, e publicadas entre 1980 e 2013. Foram utilizadas as bases de dados eletrônicas (Medline, Embase, Lilacs, Scielo, NHS EED, HTA database, Bireme e BVS ECO); os índices de citação (Scopus, Web of science) e Sisrebrats. Resultados: Foram incluídos 535 artigos, dos quais 36,8% foram considerados AES completas, sendo 39,1% análises de custo-efetividade. Quase metade (46,4%) dos estudos não relatou o tipo de análise conduzida, desses 91,9% eram AES parciais. Entre as que informaram, houve concordância entre o relato e o conduzido em 71,4% dos estudos. As modalidades das tecnologias, mais frequentemente, avaliadas foram procedimentos (34,8%) e medicamentos (28,8%) cujo objetivo principal era o de tratamento (72,1%). As três categorias de doenças cujas tecnologias foram, mais frequentemente, avaliadas foram: doenças infecciosas (17,4%), doenças do aparelho circulatório (12,9%) e neoplasia (10,3%). Entre as tecnologias avaliadas pelos estudos incluídos, apenas 64 haviam sido objeto de análise por comissões nacionais de incorporação (CITEC e CONITEC). A maioria dos artigos foi conduzida por autores da academia (65,1%), que se concentram, principalmente, na região Sudeste (73,6%) e Sul (12,5%). O principal veículo de publicação foram as revistas nacionais (72,5%), com escopo médico (55,5%). Apenas 43,5% dos estudos relataram a fonte de financiamento e 36,1% relataram presença de conflito de interesse. Setenta e nove por cento das AES completas obtiveram resultados favoráveis para as tecnologias avaliadas. Com relação à qualidade do relato, apenas 6,6% dos estudos relataram todos os itens avaliados no checklist, mas 47,7% foram considerados em conformidade (relato minimamente satisfatório). Alguns itens como 1) métodos utilizados para mensuração dos dados de custos, 2) taxa de desconto, 3) fontes de financiamento, e 4) conflitos de interesse foram relatados em apenas metade dos estudos. A qualidade do relato apresentou associação estatística significativa (p < 0,001) com o período de publicação (estudos mais recentes apresentaram maior qualidade) e com a presença de conflito de interesse (estudos com conflito de interesse apresentaram maior qualidade). As fontes de dados clínicos, de uso de recursos e de custos foram considerados com melhor nível de evidência quando comparadas às fontes de utilidade. Nos últimos anos, houve um aumento da produção de análises de custo-utilidade, porém a maioria dos estudos utilizou utilidades de outros países validadas por painéis de especialistas brasileiros. Conclusão: Um grande número de AES foi publicado no Brasil entre 1980 e 2013. A qualidade do relato foi considerada satisfatória, principalmente na AES publicadas mais recentemente. Para que as AES possam aumentar sua contribuição nos processos de decisão nacionais, são necessários esforços para melhora da qualidade dos relatos, transparência e padronização da metodologia utilizada e o aperfeiçoamento do sistema de revisão pelos pares nas revistas nacionais não específicas em economia da saúde / Introduction: Health Economic Evaluation (HEE) have participated as a supportive tool to decision-making in health sector. In Brazil, their use has been widespread in the last decade having become mandatory as part of the processes for new technologies in the Brazilian Unified National Health System. Although many Health Economic Evaluation have been conducted, there are no studies that have systematically reviewed the production and quality of Brazilian evaluations. Objective: To systematically review and evaluate the quality of reporting of published studies of health economic evaluation developed in Brazil. Methods: Was conducted a systematic review including full and partial HEE developed in Brazil and published between 1980 and 2013. Electronic databases (Medline, Embase, Lilacs, Scielo, NHS EED, HTA database, Bireme and the BVS ECO); citation indexes (Scopus, Web of science) and Sisrebrats were searched. Results: We included 535 articles, of which 36.8% were considered full HEE, being 39.1% cost-effectiveness analysis. Almost half (46.4%) of the studies did not report the type of analysis conducted, of these 91.9% were partial HEE. Among the reported, there was 71.4% agreement between the reported and conducted in the studies. The most frequent evaluated modalities of technologies were procedures (34.8%) and drugs (28.8%), whose main objective was treatment (72.1%). The three most often evaluated categories of diseases were infectious diseases (17.4%), cardiovascular diseases (12.9%) and cancer (10.3%). Among the technologies evaluated by the included studies, only 64 had been the subject of analysis by incorporating national commissions (CITEC or CONITEC). Most articles were developed by Authors from academia (65.1%), who are mainly concentrated in the Southeast (73.6%) and South (12.5%) regions. The main vehicles for publication were national journals (72.5%), with medical scope (55.5%). Only 43.5% of the studies reported the source of funding and 36.1% reported conflict of interest. Seventy-nine percent of the full HEE obtained favourable results for the evaluated technologies. Regarding the quality of reporting, only 6.6% of the studies had all items evaluated in the checklist, but 47.7% was considered to be in accordance with the reporting requirements (minimally satisfactory reporting). Items such as 1) methods used to measure the cost data, 2) discount rate, 3) funding sources, and 4) conflicts of interest were reported in only half of the studies. The quality of reporting was significantly related (p < 0.001) to the publication period (more recent studies presented higher quality) and the presence of conflict of interest (presence of conflict of interest presented higher quality). Compared to the utilities, the clinical effect size, resources, and costs data were mostly estimated based on high-ranked evidence. In recent years, there has been an increase in production of cost-utility analysis, but most studies used utilities from other countries validated by Brazilian expert panels. Conclusion: A large number of HEE was published in Brazil between 1980 and 2013. The quality of reporting was considered satisfactory, particularly in most recently published HEE. To increase their contribution in national decision-making processes, efforts are needed in order to improve the quality of reports, transparency and standardization of the methodology and the improvement of the peer-review system in national non-specific journals of health economics

L’objectif principal de cette thèse est d’évaluer le coût social des cancers des voies respiratoires d’origine professionnelle en France. Une synthèse des données épidémiologiques disponibles dans la littérature est réalisée. La méthode des risques attribuables est mobilisée pour estimer les nombres de cas (incidents, prévalents et de décès) de cancers du poumon, des naso-sinus et des mésothéliomes de la plèvre imputables à l’amiante, aux fumées d’échappement des moteurs diesel, aux peintres, à la silice cristalline, aux poussières de bois et aux poussières de cuir. Nous évaluons ensuite le coût que représentent ces cas de cancer pour la société selon la méthode du coût de la maladie. Pour prendre en compte de manière exhaustive les coûts indirects nous développons un arbre de décision permettant d’estimer la probabilité d’être concerné par chaque catégorie de coût. Nous mettons en place des modèles d’évaluations spécifiques des cancers pour chaque catégorie de coût qui nous permettent d’estimer, selon les approches par l’incidence et par la prévalence, les coûts directs (hospitaliers et soins de ville), indirects de morbidité (absentéisme et présentéisme) et de mortalité dans les sphères marchande et non marchande. Pour l’année 2010, le coût social des cancers du poumon, des naso-sinus et des mésothéliomes de la plèvre imputables à l’amiante, aux fumées d’échappement des moteurs diesel, aux peintres, à la silice cristalline, aux poussières de bois et aux poussières de cuir est estimé en France entre 986 et 1 248 millions d’euros selon l’approche par la prévalence et entre 1 223 et 1 586 millions d’euros selon l’approche par l’incidence dont 760 à 806 millions d’euros uniquement pour l’amiante. / The main objective of this thesis is to evaluate the social cost of respiratory cancer attributable to occupational risk factors in France. A summary of the available epidemiological data in the literature is performed. By using the Medline database, a review of the literature restricted to meta-analysis highlights the relative risk data available. The method of Attributable Risks (AR) is mobilized to estimate the numbers of lung, sinonasal and mesothelioma cancer cases caused by asbestos, exhaust fumes from diesel engines, painters, crystalline silica, wood dust and leather dust. We then assess the costs of these cancer cases for the french society using the Cost Of Illness (COI) method. To take into account all indirect costs we develop a decision tree to estimate the probability of being involved in each cost category. We set up cancer-specific assessment models for each category of costs that allow us to estimate, according to incidence-based and prevalence-based approaches, direct costs (hospital and ambulatory care), indirect costs of morbidity (absenteeism and presenteeism) and mortality in the market and nonmarket spheres. For 2010, the social cost of lung, sinonasal and mesothelioma cancer cases caused by asbestos, exhaust fumes from diesel engines, painters, crystalline silica, dust wood and leather dust in France is estimated between 986 and 1 248 million euros according to prevalence-based approach and between 1 223 and 1 586 million euros according to incidence-based approach among which 760 to 806 million euros only for asbestos.